I could see that happening ... 200ma, that is. Seems unlikely, though. I don't think ASCO will be any big deal for the sp. That is just my opinion. It would be very unusual for any preliminary efficacy results to come out, and I think some level of safety is expected and is priced in. Or at least WAS priced in. I think the primary reason for this softness is a safety concern stemming from the delay starting cohort 3.